TN2009000049A1 - A pyrrolopyrazin as syk-kinase inhibitor - Google Patents

A pyrrolopyrazin as syk-kinase inhibitor

Info

Publication number
TN2009000049A1
TN2009000049A1 TN2009000049A TN2009000049A TN2009000049A1 TN 2009000049 A1 TN2009000049 A1 TN 2009000049A1 TN 2009000049 A TN2009000049 A TN 2009000049A TN 2009000049 A TN2009000049 A TN 2009000049A TN 2009000049 A1 TN2009000049 A1 TN 2009000049A1
Authority
TN
Tunisia
Prior art keywords
pyrrolopyrazin
syk
kinase inhibitor
prodrugs
compound
Prior art date
Application number
TN2009000049A
Other languages
English (en)
Inventor
Elizabeth M Allen
Kin T Yu
Timothy A Gillespy
A Zilberstein
Paul Eynott
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of TN2009000049A1 publication Critical patent/TN2009000049A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TN2009000049A 2006-09-11 2009-02-17 A pyrrolopyrazin as syk-kinase inhibitor TN2009000049A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82516806P 2006-09-11 2006-09-11
PCT/US2007/078103 WO2008033798A2 (fr) 2006-09-11 2007-09-11 Inhibiteur de kinases

Publications (1)

Publication Number Publication Date
TN2009000049A1 true TN2009000049A1 (en) 2010-08-19

Family

ID=39032357

Family Applications (2)

Application Number Title Priority Date Filing Date
TN2009000049A TN2009000049A1 (en) 2006-09-11 2009-02-17 A pyrrolopyrazin as syk-kinase inhibitor
TN2009000050A TN2009000050A1 (en) 2006-09-11 2009-02-17 Production method of methane gas from olive mill waste

Family Applications After (1)

Application Number Title Priority Date Filing Date
TN2009000050A TN2009000050A1 (en) 2006-09-11 2009-02-17 Production method of methane gas from olive mill waste

Country Status (32)

Country Link
US (2) US8658649B2 (fr)
EP (1) EP2094708B1 (fr)
JP (1) JP5161237B2 (fr)
KR (1) KR101443056B1 (fr)
CN (2) CN103804383A (fr)
AR (1) AR062745A1 (fr)
AU (1) AU2007296592B8 (fr)
BR (1) BRPI0716781A2 (fr)
CA (1) CA2663175C (fr)
CL (1) CL2007002617A1 (fr)
CO (1) CO6160236A2 (fr)
CR (1) CR10636A (fr)
DK (1) DK2094708T3 (fr)
ES (1) ES2437318T3 (fr)
GT (1) GT200900055A (fr)
HN (1) HN2009000455A (fr)
IL (1) IL197381A (fr)
MA (1) MA30781B1 (fr)
MX (1) MX2009002616A (fr)
MY (1) MY148107A (fr)
NI (1) NI200900021A (fr)
NO (1) NO20091265L (fr)
NZ (1) NZ575496A (fr)
PE (1) PE20081372A1 (fr)
PT (1) PT2094708E (fr)
RU (1) RU2440352C2 (fr)
TN (2) TN2009000049A1 (fr)
TW (1) TWI399379B (fr)
UA (1) UA94622C2 (fr)
UY (1) UY30584A1 (fr)
WO (1) WO2008033798A2 (fr)
ZA (1) ZA200901073B (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2250172T3 (da) 2008-02-25 2012-01-16 Hoffmann La Roche Pyrrolopyrazinkinaseinhibitorer
WO2009106445A1 (fr) 2008-02-25 2009-09-03 F. Hoffmann-La Roche Ag Inhibiteurs de kinase pyrrolopyrazine
CA2713710A1 (fr) 2008-02-25 2009-09-03 F. Hoffmann-La Roche Ag Inhibiteurs de la pyrrolopyrazine kinase
ATE522534T1 (de) * 2008-02-25 2011-09-15 Hoffmann La Roche Pyrrolopyrazin-kinasehemmer
BRPI0907928A2 (pt) 2008-02-25 2015-07-28 Hoffmann La Roche Inibidores de pirrolopirazina quinase.
EP2285378A1 (fr) * 2008-03-10 2011-02-23 Sanofi-Aventis Traitement pour des troubles oculaires
FR2929851B1 (fr) 2008-04-09 2012-11-30 Centre Nat Rech Scient Molecules inhibant une voie metabolique impliquant la proteine tyrosine kinase syk et procede d'identification de ces molecules
PA8851701A1 (es) 2008-12-03 2010-07-27 Sanofi Aventis Tratamiento para la glomerulonefritis
MX2011004793A (es) * 2008-12-04 2011-05-30 Sanofi Aventis Formas cristalinas.
AR074776A1 (es) * 2008-12-18 2011-02-09 Sanofi Aventis Metodo para tratar la degeneracion macular; modulando el sistema inmunitario del paciente
US20110112101A1 (en) * 2009-03-05 2011-05-12 Sanofi-Aventis Treatment for ocular-related disorders
AR075869A1 (es) * 2009-03-19 2011-05-04 Sanofi Aventis Sintesis de azaindoles
PE20130188A1 (es) 2009-12-23 2013-02-21 Takeda Pharmaceutical Pirrolidinonas heteroaromaticas fusionadas como inhibidores de syk
US8518945B2 (en) 2010-03-22 2013-08-27 Hoffmann-La Roche Inc. Pyrrolopyrazine kinase inhibitors
US8481541B2 (en) 2010-03-22 2013-07-09 Hoffmann-La Roche Inc. Pyrrolopyrazine kinase inhibitors
TWI496785B (zh) 2010-05-20 2015-08-21 Hoffmann La Roche 吡咯并吡激酶抑制劑
MX2012013378A (es) * 2010-05-20 2013-01-24 Hoffmann La Roche Derivados de pirrolo [2, 3-b] pirazina-7-carboxamida y sus uso como inhibidores de cinasa janus (jak) y cinasa tirosina del brazo (syk).
EP2441755A1 (fr) 2010-09-30 2012-04-18 Almirall, S.A. Dérivés de pyridine et isoquinoline comme inhibiteurs des kinases Syk et JAK
EP2489663A1 (fr) 2011-02-16 2012-08-22 Almirall, S.A. Composés en tant qu'inhibiteurs de la syk kinase
US9056873B2 (en) 2011-06-22 2015-06-16 Takeda Pharmaceutical Company Limited Substituted 6-aza-isoindolin-1-one derivatives
KR20150043323A (ko) * 2012-08-21 2015-04-22 에프. 호프만-라 로슈 아게 비장 티로신 키나제 억제제로서 피롤로[2,3-b]피라진
EA031601B1 (ru) 2013-07-31 2019-01-31 Джилид Сайэнс, Инк. Ингибиторы syk
BR112021018168B1 (pt) 2019-03-21 2023-11-28 Onxeo Composição farmacêutica, combinação e kit compreendendo uma molécula dbait e um inibidor de quinase para o tratamento de câncer
AU2020378630A1 (en) 2019-11-08 2022-05-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (fr) 2020-01-22 2021-07-29 Onxeo Nouvelle molécule dbait et son utilisation
CN116969927B (zh) * 2023-06-07 2024-03-19 中南民族大学 一种从荜茇中提取分离的化合物及该化合物在制备抗炎药物中的应用

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1141949A (en) 1966-02-23 1969-02-05 Sterling Drug Inc 7-azaindole derivatives
US3992392A (en) 1973-04-27 1976-11-16 The Ohio State University Research Foundation Synthesis of indoles from anilines and intermediates therein
SE9100920D0 (sv) 1991-03-27 1991-03-27 Astra Ab New active compounds
EP0763035A4 (fr) 1994-06-09 1997-10-01 Smithkline Beecham Corp Antagonistes du recepteur de l'endotheline
FR2732969B1 (fr) 1995-04-14 1997-05-16 Adir Nouveaux composes pyridiniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
ES2215242T3 (es) 1996-11-19 2004-10-01 Amgen Inc. Agentes antiinflamatorios de pirrol condensado sustituido con arilo y heteroarilo.
US6312835B1 (en) 1997-02-13 2001-11-06 Queen's University At Kingston Luminescent compounds and methods of making and using same
CN1134439C (zh) 1997-03-19 2004-01-14 艾博特股份有限两合公司 吡咯并[2,3d]嘧啶类化合物及它们作为酪氨酸激酶抑制剂的用途
WO1998047899A1 (fr) 1997-04-24 1998-10-29 Ortho-Mcneil Corporation, Inc. Pyrrolopyridines substituees utilisees dans le traitement des maladies inflammatoires
JP3711238B2 (ja) 1997-08-05 2005-11-02 ファイザー・プロダクツ・インク 神経ペプチドＹ受容体アンタゴニストとしての４−アミノピロ−ル（３，２−ｄ）ピリミジン
KR100378937B1 (ko) 1997-10-20 2003-05-09 에프. 호프만-라 로슈 아게 바이사이클릭 키나아제 억제제
AU767599B2 (en) 1998-03-06 2003-11-20 Metabasis Therapeutics, Inc. Novel prodrugs for phosphorus-containing compounds
EP1070064A1 (fr) 1998-04-02 2001-01-24 Merck & Co., Inc. Antagonistes de l'hormone liberant la gonadotropine (gnrh)
JP2002510630A (ja) 1998-04-02 2002-04-09 メルク エンド カムパニー インコーポレーテッド 性腺刺激ホルモン放出ホルモン拮抗薬
DE69942801D1 (de) 1998-05-26 2010-11-11 Chugai Pharmaceutical Co Ltd Heterozyklische indolderivate und mono- oder diazaindol-derivate
TR200101395T2 (tr) 1998-09-18 2001-11-21 Basf Ag. Kinaz engelleyiciler olarak 4-Aminopyrrolopyrimidin'ler
PE20010306A1 (es) 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
EP1263759B1 (fr) 1999-12-24 2010-09-08 Aventis Pharma Limited Azaindoles
GB9930698D0 (en) * 1999-12-24 2000-02-16 Rhone Poulenc Rorer Ltd Chemical compounds
US6770666B2 (en) 1999-12-27 2004-08-03 Japan Tobacco Inc. Fused-ring compounds and use thereof as drugs
YU54202A (sh) 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
DE10009000A1 (de) 2000-02-25 2001-08-30 Basf Ag Verfahren zur Herstellung substituierter Indole
WO2001070743A1 (fr) 2000-03-20 2001-09-27 Axys Pharmaceuticals, Inc. Inhibiteurs de la protease exempte d'amidine
JP2001302667A (ja) * 2000-04-28 2001-10-31 Bayer Ag イミダゾピリミジン誘導体およびトリアゾロピリミジン誘導体
US6673923B2 (en) 2000-05-03 2004-01-06 Tularik Inc. Pyrazole antimicrobial agents
MXPA02010763A (es) 2000-06-14 2003-03-10 Warner Lambert Co Heterociclicos biciclos-6,5 fusionados.
WO2002028831A1 (fr) 2000-10-02 2002-04-11 Merck & Co., Inc. Inhibiteurs de la prenyl-proteine transferase
GB0115109D0 (en) * 2001-06-21 2001-08-15 Aventis Pharma Ltd Chemical compounds
WO2003000690A1 (fr) 2001-06-25 2003-01-03 Aventis Pharmaceuticals Inc. Synthese de composes heterocycliques faisant appel a une technologie micro-onde
AR035543A1 (es) 2001-06-26 2004-06-16 Japan Tobacco Inc Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con
JP5039268B2 (ja) 2001-10-26 2012-10-03 アベンティス・ファーマスーティカルズ・インコーポレイテツド ベンゾイミダゾールおよび類縁体および蛋白キナーゼ阻害剤としてのその使用
US20040082365A1 (en) * 2002-07-18 2004-04-29 Celerica Ltd Digitization and transmitting cellular RF signals by several light wavelengths
EP1388541A1 (fr) 2002-08-09 2004-02-11 Centre National De La Recherche Scientifique (Cnrs) Pyrrolopyrazines utilisées comme inhibiteurs de kinases
WO2005014543A1 (fr) 2003-08-06 2005-02-17 Japan Tobacco Inc. Compose a cycle condense utilise comme inhibiteur de la polymerase du vhc
EP2239262A3 (fr) * 2004-07-27 2011-10-19 SGX Pharmaceuticals, Inc. Composés hétérocycliques annelés comme modulateurs de kinases
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
FR2876582B1 (fr) 2004-10-15 2007-01-05 Centre Nat Rech Scient Cnrse Utilisation de derives de pyrrolo-pyrazines pour la fabrication de medicaments pour le traitement de la mucoviscidose et de maladies liees a un defaut d'adressage des proteines dans les cellules
JP2008519036A (ja) 2004-11-08 2008-06-05 バクスター・インターナショナル・インコーポレイテッド チューブリン阻害化合物のナノ粒子組成物
EP1814882A1 (fr) * 2004-11-22 2007-08-08 Vertex Pharmaceuticals Incorporated Pyrrolopyrazines et pyrazolopyrazines convenant inhibiteurs de proteines-kinases
US20110112101A1 (en) 2009-03-05 2011-05-12 Sanofi-Aventis Treatment for ocular-related disorders

Also Published As

Publication number Publication date
ES2437318T3 (es) 2014-01-10
UA94622C2 (en) 2011-05-25
KR101443056B1 (ko) 2014-09-22
RU2009113615A (ru) 2010-10-20
TN2009000050A1 (en) 2010-08-19
MA30781B1 (fr) 2009-10-01
CN101511838A (zh) 2009-08-19
US8658649B2 (en) 2014-02-25
BRPI0716781A2 (pt) 2014-11-18
NI200900021A (es) 2010-01-29
WO2008033798A3 (fr) 2008-05-15
MX2009002616A (es) 2009-03-24
TWI399379B (zh) 2013-06-21
AU2007296592B8 (en) 2012-01-12
IL197381A (en) 2013-11-28
MY148107A (en) 2013-02-28
GT200900055A (es) 2010-07-28
CR10636A (es) 2009-03-20
CA2663175C (fr) 2012-03-13
NZ575496A (en) 2011-09-30
CL2007002617A1 (es) 2008-05-16
CA2663175A1 (fr) 2008-03-20
IL197381A0 (en) 2009-12-24
AU2007296592A1 (en) 2008-03-20
UY30584A1 (es) 2008-05-02
CO6160236A2 (es) 2010-05-20
WO2008033798A2 (fr) 2008-03-20
US20100035884A1 (en) 2010-02-11
EP2094708A2 (fr) 2009-09-02
PE20081372A1 (es) 2008-11-27
JP5161237B2 (ja) 2013-03-13
AU2007296592B2 (en) 2011-12-15
DK2094708T3 (da) 2014-01-27
EP2094708B1 (fr) 2013-10-23
US20140142110A1 (en) 2014-05-22
HN2009000455A (es) 2012-02-13
ZA200901073B (en) 2009-12-30
NO20091265L (no) 2009-04-03
KR20090063214A (ko) 2009-06-17
AR062745A1 (es) 2008-12-03
JP2010502767A (ja) 2010-01-28
TW200829590A (en) 2008-07-16
CN103804383A (zh) 2014-05-21
PT2094708E (pt) 2014-01-07
RU2440352C2 (ru) 2012-01-20

Similar Documents

Publication Publication Date Title
TN2009000049A1 (en) A pyrrolopyrazin as syk-kinase inhibitor
MY149512A (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors
PT1940839E (pt) Inibidores de piridopirimidinona pi3k alfa
WO2006123113A3 (fr) Composes chimiques
HK1154002A1 (en) Imidazopyridazinecarbonitriles useful as kinase inhibitors
MX2009000884A (es) Derivados de piridizinona.
PH12012502057A1 (en) Compounds for inhibiting mitotic progression
MX2009003834A (es) Derivados de pirrolidina como inhibidores de iap.
SG179418A1 (en) Inhibitors of the hedgehog pathway
MD4582C1 (ro) Derivaţi ai 1-fenil-1H-benzimidazolului ca inhibitori ai protein kinazei
NZ585460A (en) Inhibitors of human phosphatidyl-inositol 3-kinase delta
WO2009016460A8 (fr) Composés pyrazoles
MX2010004263A (es) Inhibidores de quinasa c-fms.
MY151003A (en) Stable pharmaceutical composition comprising a pyrimidine-sulfamide
HK1133012A1 (en) Pyrimidinones as casein kinase ii (ck2) modulators
MX2009005691A (es) Inhibidores de la enzima de diacilglicerol o-acilotransferasa tipo i.
WO2008022286A3 (fr) petits inhibiteurs moléculaires de la kynurénine-3-monooxygénase
TNSN08191A1 (en) Kinase inhibitors
TN2010000038A1 (en) Organic compounds
MX2013004162A (es) Composiciones farmaceuticas que contienen un inhibidor de dgat1.
MY147188A (en) Substituted imidazole compounds as ksp inhibitors
UA97821C2 (en) Cyclized derivatives as eg-5 inhibitors
EA200900631A1 (ru) Замещённые пиразолы и триазолы, как ингибиторы кбв (кинезин-белок веретена)
MX2008016358A (es) Derivados de tiazolil-urea como inhibidores de cinasa de fosfatidil-inositol-3.
TNSN08242A1 (en) 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof